The IRS created the "wash sale" rule to prevent investors

New Post Public Reply Private Reply Replies (1) Message Board
BooDog Drano #14248
The IRS created the "wash sale" rule to prevent investors from recognizing artificial losses by first selling a security for a loss and then repurchasing the same security within a short period of time.

A wash sale is a double transaction on "substantially similar" securities in a 61-day window. The 61 days includes the date of the trade plus 30 days before and 30 days after. This means that if you hold a stock, buy additional shares and sell it for a loss within 30 days of the replacement purchase, or you sell stock you own at a loss and then repurchase it within 30 days of the sale loss, your trade is considered a wash sale.

Wash Sales & Cost Basis

For example, say you purchase 100 shares of XYZ for $25 per share on Feb. 10. Nine days later, on Feb. 19, XYZ drops to $22 per share and you sell your 100 shares. You have a capital loss of $3 per share, or $300, which may be tax-deductible. If on Feb. 26 you bought the same security for $22.50 per share, this would be considered a wash sale because you sold and repurchased shares of the same stock within only a few days. Without the wash sale rule, the result would be that you could possibly have a tax deduction for your loss, but you would still own the shares, which is why it's sometimes called an "artificial" loss.

With the wash sale rule in place, the loss is deferred until the replacement shares are sold. In this example, that means your $300 loss would be added to your cost basis on the shares you repurchased on Feb. 26 to get an accurate capital gain/loss figure when you sell those shares.

Normally, your cost basis is the total amount of money you have invested in the stock, calculated by multiplying the per-share price by the number of shares purchased. For the Feb. 26 purchase, your normal cost basis would be $2,250 ($22.50 x 100). However, because the purchase was part of a wash sale, your cost basis would have to include your previous losses from the 100 shares sold on Feb. 19, making it $2,550 ($2,250 + $300). Thus, when you sell the replacement shares of XYZ, you will have to calculate your capital gains or losses using $2,550 as your cost basis to account for your previous losses. A higher cost basis may potentially be beneficial in the future from a tax perspective because any capital gains will appear lower and capital losses will appear higher.

Innovation Pharmaceuticals Inc (IPIX) Stock Research Links

IPIX Board Company Profile Buy Rating Time & Sales News Filings Financials
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Epson Unveils Early Black Friday Tech Deals

Updated Category News Views 79

Diving Headfirst into Holiday Tech Splurging The holiday hustle is upon us, folks, and Epson's stepping up with early Black Friday deals that'll have tech heads scrambling. They’re cutting prices up to $250 on their swanky home lineup—projectors, printers, scanners, you name it. This ain't just about making someone else smile, though; it's about the sweet spot where...

Continue Reading
Kava Meets Comics: A New Spot in King of Prussia

Updated Category News Views 96

A Social Revolution in King of Prussia Look, this ain't your typical bar review. We're talking about the Uncanny Comics and Kava Bar at King of Prussia Mall—where comic books, collectible treasures, and good company collide with a South Pacific vibe. Kava: Beyond Just Another Drink First off, if you're scratching your head about kava, don't fret. It's a beverage made...

Continue Reading
Chronograph Expands in EMEA Amid Growing Market Needs

Updated Category News Views 21

Dan Tyler's Role: Meeting a Growing Demand When it comes to expanding your reach in the business world, bringing fresh blood to the team isn't just about filling a seat—it's about filling the needs of your market. That's exactly what Chronograph is doing by appointing Dan Tyler as their Client Development Director in London. Tyler's experience is like a Swiss army knife...

Continue Reading
Ziva Surgical Aims to Revolutionize Cancer Surgery

Updated Category News Views 61

Breaking Ground in Surgical Oncology In a world where surgical precision teeters between sight and touch, Ziva Surgical has staked its claim. Popping out of its shell like a tenacious crab, the folks formerly known as OncoRes Medical are done just playing in the lab. Turns out, a bit of Australian grit can shake up global surgery practices — who knew? Bringing Science...

Continue Reading
Scrutinizing Mergers: How PAG, ARX, DSGR Deals Stack Up

Updated Category News Views 38

Questioning the Value of Recent Deals It seems like everyone's wearing rose-colored glasses when a fancy deal gets announced. But dig beneath the headlines, and you might find shareholders grumbling if firms like Penske Automotive Group, Accelerant Holdings, and Distribution Solutions Group are getting short-changed. The crux? Insiders making a pretty penny while ordinary...

Continue Reading
Minerva Foods' Profit Struggles Despite Revenue Growth

Updated Category News Views 51

Setting the Stage: Minerva Foods' Latest Report Walking through the jungle of financial statements, few things are clear-cut. Minerva Foods handed out its latest report, stirring both optimism and concern among the suits at the table. Here's the brass tacks of it: a 9.5% boost in net revenue drumming up R$56.2 billion over twelve months. Sounds solid, huh? Yet, lurking...

Continue Reading
Group 1 Expands with Porsche Atlanta Northwest Acquisition

Updated Category News Views 35

Porsche Atlanta Northwest Joins Group 1 Automotive This ain't just some humdrum industry announcement, folks. Group 1 Automotive, the Houston-based heavyweight, has tightened its grip on the Atlanta car scene by welcoming Porsche Atlanta Northwest into the fold. This development marks the latest notch in Group 1’s belt as they continue gobbling up Atlanta-area...

Continue Reading
Universal Music CFO to Speak at Major Tech Conference

Updated Category News Views 42

UMG Steps into the Spotlight at Morgan Stanley Event Music, money, and technology—it's a compelling trio. Universal Music Group (EURONEXT: UMG) is sending its heavyweights, Matt Ellis and Michael Nash, to the Morgan Stanley European Technology, Media & Telecom Conference on November 18, 2026. This isn't just any run-of-the-mill industry hobnob. We're talking about the...

Continue Reading
Frasle Mobility's Resilience Despite Market Woes in 3Q26

Updated Category News Views 50

Economic Wrangling: What Happened? Here comes Frasle Mobility, standing tall against a tide trying to pull everyone under. Ending the third quarter of 2026, they dropped a modest net revenue of R$1.38 billion. A light dip of 1.9% year-over-year, but don't let that fool you. Amid the chaos, these folks managed to expand their gross margin and kept their financials...

Continue Reading
ISMP Cheers Awards Honor Vital Medication Safety Efforts

Updated Category News Views 62

Honoring Progress in Medication Safety Boy, if there's one thing that's clear in the world of healthcare, it's that nothing's more vital than patient safety. The Institute for Safe Medication Practices (ISMP) is more than a fine-toothed comb in that realm; it's basically the gold standard. Every year, they shine a light on folks and organizations wrestling with the beast...

Continue Reading

Top 5 Most Recently Viewed Articles

Investment Growth Insights: Burlington Stores Stock Journey

Updated Category News Views 213

Understanding Burlington Stores' Remarkable Growth Burlington Stores (NYSE: BURL) has consistently excelled in the retail sector over the past decade, showcasing impressive performance that has outshined the broader market. With an annualized return of 14.79%, investors in Burlington Stores would have witnessed a remarkable increase in their investment, exceeding market...

Continue Reading
Analyzing BridgeBio Pharma Inc's Short Interest Trends

Updated Category News Views 140

Understanding BridgeBio Pharma Inc's Short Interest Dynamics BridgeBio Pharma Inc (NYSE: BBIO) has recently experienced a notable shift in its short interest, with a decline of 6.31% reported since the last update. At present, there are approximately 19.38 million shares shorted, which constitutes 16.79% of the shares available for trading. This data provides a window...

Continue Reading
Shiba Inu Surges Amid Market Fluctuations and Trends

Updated Category News Views 71

Shiba Inu Price Movement Analysis Shiba Inu has recently shown some encouraging growth, with its price jumping by 3.24% in just one day to hit $0.000014. This increase is a clear indication of its resilience and growing investor interest, especially considering it has seen a 5.0% rise over the week from $0.000013. Such trends suggest that there could be a shift happening...

Continue Reading
Tonix Pharmaceuticals Secures Major Contract for Antiviral Development

Updated Category News Views 90

Tonix Pharmaceuticals Secures First Payment for Antiviral Development Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP), a dynamic biopharmaceutical company, has recently secured its first contract payment from the Defense Threat Reduction Agency (DTRA). This initiative focuses on the rapid development of small molecule broad-spectrum antiviral agents aimed at preventing...

Continue Reading
GameStop's New PR Strategy: Aiming for Future Growth

Updated Category News Views 533

GameStop's New PR Strategy on the Horizon GameStop Corporation (NYSE: GME), the prominent video game retailer, has been a focal point in the stock market, primarily due to its tumultuous trading history. Recently, the company has remained silent on earnings conference calls, raising eyebrows among investors and analysts. Current Financial Standing However, the company’s...

Continue Reading